Clinical Research Directory
Browse clinical research sites, groups, and studies.
Deucravacitinib Adherence Study
Sponsor: Wake Forest University Health Sciences
Summary
Psoriasis patients are very poorly adherent to topical treatment. If adherence issues are ignored, poor adherence may limit the real-world efficacy of deucravacitinib, too. Forty psoriasis patients recruited from Wake Forest Baptist Health Dermatology Clinic will be enrolled. Twenty will be randomized to a reporting intervention designed to promote better adherence and the remaining 20 patients will serve as controls who will not receive a reporting intervention. Through qualitative interviews of the 40 patients recruited, we plan to study the behaviors of the most adherent patients to better understand specific beliefs and behaviors of adherent patients and to identify practical, modifiable factors that can improve adherence. We will also compare treatment outcomes and efficacy of deucravacitinib between the most and least adherence patients.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2023-07-24
Completion Date
2027-03
Last Updated
2026-03-31
Healthy Volunteers
No
Conditions
Interventions
Text reminder
weekly text to remind use of drug
Locations (1)
Wake Forest University Health Sciences Department of Dermatology
Winston-Salem, North Carolina, United States